Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip?

Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity candidate WVE-007 disappointed investors.  

This immense pressure on Thursday saw WVE’s relative strength index (14-day) slip below 20, indicating extremely oversold conditions that often trigger a relief rally. 

Fundamentals

See More
  • Market Capitalization, $K 1,167,181
  • Shares Outstanding, K 188,255
  • Annual Sales, $ 42,730 K
  • Annual Income, $ -204,380 K
  • EBIT $ -215 M
  • EBITDA $ -207 M
  • 60-Month Beta -1.77
  • Price/Sales 54.19
  • Price/Cash Flow N/A
  • Price/Book 3.97

Options Overview Details

View History
  • Implied Volatility 87.97% (-4.69%)
  • Historical Volatility 202.58%
  • IV Percentile 22%
  • IV Rank 18.82%
  • IV High 199.53% on 11/05/25
  • IV Low 62.09% on 08/21/25
  • Expected Move (DTE 21) 0.89 (13.58%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 6,302
  • Volume Avg (30-Day) 5,782
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 85,632
  • Open Int (30-Day) 61,612
  • Expected Range 5.68 to 7.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.34
  • Number of Estimates 5
  • High Estimate -0.32
  • Low Estimate -0.36
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -17.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.02 +28.21%
on 03/26/26
14.32 -55.06%
on 03/11/26
-7.49 (-53.80%)
since 02/27/26
3-Month
5.02 +28.21%
on 03/26/26
19.50 -66.99%
on 01/06/26
-11.33 (-63.78%)
since 12/26/25
52-Week
5.02 +28.21%
on 03/26/26
21.73 -70.38%
on 12/09/25
-2.57 (-28.57%)
since 03/27/25

Most Recent Stories

More News
Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip?

Wave Life Sciences stock sinks as Phase 1 data for obesity drug disappoints investors. But Oppenheimer still recommends loading up on WVE shares today.

WVE : 6.36 (+2.58%)
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p

WVE : 6.36 (+2.58%)
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference...

WVE : 6.36 (+2.58%)
Wave Life Sciences: Q4 Earnings Snapshot

Wave Life Sciences: Q4 Earnings Snapshot

WVE : 6.36 (+2.58%)
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while...

WVE : 6.36 (+2.58%)
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 6.36 (+2.58%)
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 6.36 (+2.58%)
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies...

WVE : 6.36 (+2.58%)
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007...

WVE : 6.36 (+2.58%)
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 6.36 (+2.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed above 20%. The market has bounced from extreme oversold territory, indicating a possible trend reversal.

See More Share

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 8.26
2nd Resistance Point 7.37
1st Resistance Point 6.79
Last Price 6.36
1st Support Level 5.32
2nd Support Level 4.43
3rd Support Level 3.85

See More

52-Week High 21.73
Fibonacci 61.8% 15.35
Fibonacci 50% 13.38
Fibonacci 38.2% 11.40
Last Price 6.36
52-Week Low 5.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.